Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 31, 2014
Event: Entry into a Material Definitive Agreement with MannKind Corporation.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on the terms of a new commercial agreement.
| Metric | Value |
|---|---|
| Aggregate Purchase Commitment (2015-2019) | Approximately $120.1 million |
| Product | Recombinant human insulin for AFREZZA |
| Agreement Term | Through December 31, 2019 (with renewal options) |
Material Changes
The primary material change is the execution of a Supply Agreement on July 31, 2014, between MannKind Corporation and Amphastar France Pharmaceuticals S.A.S. Under this agreement, Amphastar will manufacture and supply insulin for MannKind's product AFREZZA. This represents a new revenue stream with guaranteed minimum purchase quantities.
Guidance, Outlook, and Risks
- Commitment Structure: MannKind has agreed to purchase annual minimum quantities totaling approximately $120.1 million from 2015 through 2019. Additional quantities may be purchased at MannKind's request.
- Termination and Penalties: MannKind may terminate the agreement without cause with two years' prior written notice. If terminated without cause or due to regulatory withdrawal of AFREZZA approval, MannKind must pay the full amount of all unpaid purchase commitments due over the initial term within 60 days.
- Confidentiality: The Company intends to seek confidential treatment for certain portions of the agreement.
- Future Filing: The full agreement is expected to be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2014.
Investor Verification Checklist
- Verify the specific annual breakdown of the $120.1 million commitment in the upcoming Form 10-Q.
- Confirm the regulatory status of MannKind's AFREZZA product, as regulatory withdrawal triggers immediate payment of remaining commitments.
- Review the full Supply Agreement exhibit for detailed quality standards and specific termination clauses.
- Monitor whether MannKind exercises its option to purchase quantities above the annual minimums.